Skip to main content
. 2013 Feb;15(2):143–155. doi: 10.1593/neo.121712

Figure 3.

Figure 3

(A–C) Treatment of three patient-derived pancreatic cancer cell lines with DMSO (control) and lapatinib (1.0 µM), showing relative phosphorylation of EGF and FGF family RTKs (ND, no detection of pRTK). (D and E) Western blot analysis for ERK and pERK in three patient-derived pancreatic cancer cell lines and four established cell lines after treatment with DMSO, lapatinib (1.0 µM), trametinib (0.3 µM), and combination.